Loading...
•
Mar 31, 2024
Arcellx Q1 2024 Earnings Report
Arcellx's financial results for Q1 2024 were reported, featuring collaboration revenue and a reduced net loss compared to the previous year.
Key Takeaways
Arcellx reported collaboration revenue of $39.3 million and a net loss of $7.2 million for the first quarter ended March 31, 2024. The company's cash, cash equivalents, and marketable securities totaled $691.0 million, expected to fund operations into 2027.
Arcellx had cash, cash equivalents, and marketable securities of $691.0 million as of March 31, 2024.
Collaboration revenue increased to $39.3 million, driven by changes in estimated transaction price with Kite Pharma, Inc.
Research and development expenses decreased slightly to $32.3 million due to reduced costs in the anito-cel clinical program.
Net loss decreased to $7.2 million, compared to $27.3 million for the same quarter in the previous year.
Revenue by Segment
Forward Guidance
Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...